EGFR and renal carcinoma: [391] found that the multikinase inhibitor cabozantinib upregulated EGFR expression and downregulated membrane PD‐L1 expression in renal cancer cells, thereby augmenting the in vitro cytotoxicity of CAR‐NK‐92 cells against renal carcinoma.